India reports 58,077 new COVID-19 cases in 24 hours
India’s first mRNA COVID-19 vaccine is currently in final stage of clinical trial, the government announced on Thursday.
Responding to a question at the weekly press conference, NITI Aayog (Health) member Dr. VK Paul said that a vaccine candidate from Pune-based Gennova Biopharmaceuticals, which is entirely an Indian development, is in the pipeline. final phase of clinical trial.
“Hopefully it will cross that threshold so it can be used for emergencies and regular use one day,” he said.
The official noted that the vaccine can be stored under normal cold chain conditions and transported, which is important.
So we have an excellent candidate. They also modified it for the Omicron variant that will be presented. We need the mRNA platform because it is a new platform and vaccines developed on these platforms, at least for coronavirus, have been shown to be effective around the world entire,” Paul said.
“Having a vaccine platform in India is an asset in the wake of COVID-19 and Omicron, but also for other diseases for which we are still looking for affordable, effective and sustainable vaccines, so we cherish this platform and we commend the company and the group for committing to this. As a platform, this will be important in the near future and beyond,” he added.
ICMR Director General Balram Bhargava said this is another vaccine that really establishes that India is moving towards a vaccine superpower and that these vaccines will be available for other diseases.
And because such a large proportion have been vaccinated, we are not seeing such a disastrous third surge in terms of hospitalization and mortality, he said.